Search Results

July 28, 2014

Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C

Study evaluated interferon-free combination in treatment-naïve and prior null-responder patients with all stages of liver fibrosis, including cirrhosis

Innovative Medicine

July 28, 2014

IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p

Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival

Innovative Medicine

July 25, 2014

Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA™ for use in the Treatment of Two Forms of Blood Cancer

Innovative Medicine

July 14, 2014

Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies

Submission based on first head-to-head study vs. oral treatments in real world context

Innovative Medicine

June 24, 2014

Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science

Corporate

June 19, 2014

Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces

Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer’s, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections

Innovative Medicine

June 18, 2014

Janssen Announces License Agreement With Vertex To Develop Novel Treatment For Influenza A

Innovative Medicine

June 16, 2014

New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies

Phase 3 Study Results Also Demonstrate INVOKANA® Reduces Secondary Endpoints of Body Weight and Systolic Blood Pressure

Innovative Medicine

June 12, 2014

Janssen Collaborates With ViiV Healthcare To Develop Two-Drug Single Tablet Regimen For The Maintenance Treatment Of People Living With HIV

Innovative Medicine

June 2, 2014

Ibrutinib (IMBRUVICA®) RESONATET™ Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine